Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibrilatazar - Ability Pharmaceuticals

Next Previous
Drug Profile

Ibrilatazar - Ability Pharmaceuticals

Alternative Names: ABTL-0812; LAM-182; LP-10218; SCLN-0812

Latest Information Update: 17 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lipopharma
  • Developer Ability Pharmaceuticals; SciClone Pharmaceuticals
  • Class Antineoplastics; Small molecules; Unsaturated fatty acids
  • Mechanism of Action Autophagy stimulants; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Biliary cancer; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Pancreatic cancer

Highest Development Phases

  • Phase II Endometrial cancer; Pancreatic cancer; Squamous cell cancer
  • No development reported Biliary cancer; Neuroblastoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 09 Sep 2024 Efficacy, pharmacokinetics and adverse events data from a phase II trial in Endometrial cancer released by ability pharma
  • 01 Aug 2024 Ability Pharma receives world health organization approval for ABTL0812 to receive the International Non-proprietary Name of ibrilatazar
  • 28 May 2024 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in China (PO, Liquid)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top